Maxim Group initiated coverage of Mainz Biomed B.V. with a rating of Buy and set a new price target of $14.00

H.C. Wainwright downgraded Mainz Biomed B.V. from Buy to Neutral

Cantor Fitzgerald downgraded Mainz Biomed B.V. from Overweight to Neutral

H.C. Wainwright initiated coverage of Mainz Biomed B.V. with a rating of Buy and set a new price target of $25.00

SCHEDULE 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)

6-K - MAINZ BIOMED N.V. (0001874252) (Filer)

424B3 - MAINZ BIOMED N.V. (0001874252) (Filer)

EFFECT - MAINZ BIOMED N.V. (0001874252) (Filer)

F-1 - MAINZ BIOMED N.V. (0001874252) (Filer)

6-K - MAINZ BIOMED N.V. (0001874252) (Filer)

424B3 - MAINZ BIOMED N.V. (0001874252) (Filer)

6-K - MAINZ BIOMED N.V. (0001874252) (Filer)

EFFECT - MAINZ BIOMED N.V. (0001874252) (Filer)

SCHEDULE 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)

Transaction entails executing option agreements to purchase IP portfolio associated with current ColoAlert product and the novel gene expression (mRNA) biomarkers being evaluated in ColoFuture/eAARLY DETECT Studies BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the execution of its option from Uni Targeting Research AS to acquire all of the previously licensed scientific intellectual property ("IP") for its flagship product ColoAlert, a highly efficacious, and easy-to-use detection test for colorec

Potential for ColoAlert to Emerge as the Most Robust and Accurate At-home Screening Test for Colorectal Cancer Biomarkers Demonstrated Unique Ability to Identify Curable Precancerous Colonic Polyps as well as Curable Early-Stage Colorectal Cancer BERKELEY, Calif. and MAINZ, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today it has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines S.E.C. ("TTS") to access a portfolio of novel mRNA biomarkers for potential future integration into ColoAlert,

BERKELEY, Calif. and MAINZ, Germany, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert® has received official registration with the Medicines and Healthcare products Regulatory Agency (MHRA) and is now authorized for marketing in the United Kingdom. This milestone follows the technology partnership announced earlier this year with EDX Medical Group plc, a leading UK laboratory, and represents an important step toward making Mainz Biomed's DNA-based colorectal cancer (CRC) screening test, ColoAlert, broadly accessible

BERKELEY, Calif. and MAINZ, Germany, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert®, its non-invasive colorectal cancer (CRC) screening test, has been officially registered and approved for distribution by Swissmedic, the Swiss regulatory and supervisory authority for medicinal products and medical devices. In Switzerland, CRC screening programs primarily focus on individuals between the ages of 50 and 74, with options for a biennial Fecal Immunochemical Test (FIT) or a colonoscopy every 10 years. The population in t

BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 2,222,222 units, with each unit consisting of one ordinary share (or pre-funded warrant in lieu thereof) and one Series A warrant to purchase one and one half ordinary shares for gross proceeds of approximately $3.0 million. Each unit is being sold at an effective offering price of $1.35 per unit. Each Series A warrant will be immediately exercisable at an exercise price of $1.35 per share and will expire five year

BERKELEY, Calif. and MAINZ, Germany, July 23, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a diagnostics company specializing in the early detection of cancer, today announced a collaboration with CARE diagnostica Laborreagenzien GmbH ("CARE"). CARE is currently working with more than 15 statutory health insurance companies as part of special online-based screening concepts based on the widely used fecal immuniochemical test (FIT). Thanks to the cooperation with Mainz Biomed, the range of services for risk groups can now be expanded to include the ColoAlert® test, which uses molecular genetic analysis of biomarkers in stool using PCR to

BERKELEY, Calif. and MAINZ, Germany, July 15, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today reviewed its major accomplishments of the first six months ending June 30, 2025, and provided a corporate update. The Company expects to release its half year financial results in September 2025. Key Highlights During First Half 2025 Mainz Biomed launched eAArly DETECT 2, a US feasibility study to evaluate the Company's next generation colorectal cancer (CRC) test, integrating its proprietary mRNA biomarkers, AI developed algorithm and FIT test, over a populati

BERKELEY, Calif. and MAINZ, Germany, June 25, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce that its pancreatic cancer project will receive public funding from the Investitions- und Strukturbank Rheinland-Pfalz (ISB), the development bank of the German federal state of Rheinland-Pfalz. Under the ISB's Innovation and Technology Support Program (Innovations- und Technologieförderungsprogramm), the state will fund up to 50% of the project's total costs. This direct governmental support represents a strong endorsement of the scientific a

BERKELEY, Calif. and MAINZ, Germany, June 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the commencement of the next phase in its PancAlert project, a research initiative focused on developing a non-invasive blood-based screening test for the early detection of pancreatic cancer. The feasibility phase is intended to confirm the discovery analysis performed in early 2025 in partnership with Liquid Biosciences which demonstrated sensitivity of 95% with specificity of 98% for the detection of pancreatic cancer in blood samples. Having previous

BERKELEY, Calif. and MAINZ, Germany, May 19, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 2,000,000 units, with each unit consisting of one ordinary share (or pre-funded warrant in lieu thereof), one Series A warrant to purchase one ordinary share, and one Series B warrant to purchase one ordinary share for gross proceeds of approximately $4.0 million. Each unit is being sold at an effective offering price of $2.00 per unit. Each Series A warrant will be immediately exercisable at an exercise price of $2

Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, Calif. and MAINZ, Germany, May 16, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it intends to provide an interim read out of its eAArly DETECT 2 feasibility study by the end of summer 2025. The study is evaluating the Company's next-generation colorectal cancer (CRC) screening test that integrates Mainz Biomeds proprietary mRNA biomarkers, an AI-devel

BERKELEY, Calif. and MAINZ, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, has entered into a technology partnership with UK-based EDX Medical Group plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalized treatments for cancer, cardiovascular and infectious diseases. Under the agreement, EDX Medical will access Mainz Biomed's molecular diagnostic technology as part of the expansion of its portfolio of products for sale in the UK. "We are delighted to join forces with EDX Medical Limited t

SC 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)

SC 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)

SC 13G - MAINZ BIOMED N.V. (0001874252) (Subject)

SC 13G - MAINZ BIOMED N.V. (0001874252) (Subject)

BERKELEY, Calif. and MAINZ, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, has entered into a technology partnership with UK-based EDX Medical Group plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalized treatments for cancer, cardiovascular and infectious diseases. Under the agreement, EDX Medical will access Mainz Biomed's molecular diagnostic technology as part of the expansion of its portfolio of products for sale in the UK. "We are delighted to join forces with EDX Medical Limited t

BERKELEY, Calif. and MAINZ, Germany, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the addition of Petra Smeltzer Starke as a Brand Ambassador for the Company. As Brand Ambassador she will help the Company in the development and dissemination of messaging focused on the importance of early detection of colorectal cancer. "We are excited about Petra joining our team as Brand Ambassador. Her broad and deep experience will be invaluable to us as we bring our next generation colorectal cancer screening product to market, with the

Former Natera Manager will oversee all aspects of sales and support in EMEA, ensuring the continued commercialization of ColoAlert® across the region BERKELEY, Calif. and MAINZ, Germany, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is proud to announce the appointment of Tarrin Khairi-Taraki as Vice President of Commercial Operations, EMEA. Tarrin will play a pivotal role in steering Mainz Biomed's continued success, focusing on the commercialization of its flagship product, ColoAlert® — a highly effective and user-friendly at-home detection test f

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Amy Levin, RAC, as Vice President of Regulatory Affairs. In this role, Ms. Levin will be in charge of guiding the implementation and regulatory, clinical trial and quality initiatives that are related to in vitro diagnostics. She will contribute to key milestones for the FDA submission process for ColoAlert, the Company's highly efficacious and easy-to-use DNA-based detection test for colorectal cancer (CRC). She will also be responsib

Dr. Dreismann, Former Roche Molecular Diagnostics CEO, and Mr. Tibbitts, a Highly-accomplished Life-Sciences Executive, Provide Extensive Experience in Diagnostics and Financial Strategy Company to Hold Extraordinary General Meeting Week of December 12, 2022 BERKELEY, Calif. and MAINZ, Germany, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that its Nominating Committee and Board of Directors nominated Dr. Heiner Dreismann as Chairman of the Board and Gregory Tibbitts to its Board of Directors. The Company's Board

Distinguished Professor Emeritus of Medicine at Indiana University School of Medicine, Chancellor's Professor at Indiana University Purdue University Indianapolis, and Director of Endoscopy at Indiana University Hospital in Indianapolis BERKELEY, Calif. and MAINZ, Germany, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Douglas K. Rex to its Medical Advisory Board (MAB). Dr. Rex is the latest industry expert to join the MAB which was established to support Mainz's forthcoming U.S. pivotal trial for ColoAlert, th

127% year-over-year increase in ColoAlert revenueMid-year cash balance of $26 Million BERKELEY, Calif. and MAINZ, Germany, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the first half of the fiscal year ended June 30, 2022. Key Corporate & Product Development Highlights Accelerated international commercial activities for ColoAlert, the Company's highly efficacious and easy-to-use detection test for colorectal cancer (CRC)Appointed Darin Leigh, former Abbott and Luminex executive, as Chief Commercial OfficerEs

Dr. Turgeon is an esteemed Clinical Professor at University of Michigan Health and clinical translational researcher with specific research interest in colon cancer and chemopreventionMainz Biomed's Medical Advisory Board to bring together a highly distinguished group of multi-disciplinary experts from across gastroenterology, clinical research and diagnostics to support its forthcoming U.S. pivotal trial for ColoAlert BERKELEY, Calif. and MAINZ, Germany, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. D. Kim T

BERKELEY, Calif. and MAINZ, Germany, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Frank Krieg-Schneider as Vice President of Development. "Within the field of advanced diagnostics, it's essential to have a strong and experienced team able to both innovate and to execute," said Guido Baechler, Chief Executive Officer of Mainz Biomed. "We're very excited to welcome Frank to our team who has honed his skills developing complex diagnostics tests for some of the largest and most successful organizations in the diag

Renowned Experts to Support ColoAlert's U.S. Pivotal Clinical Trial and Development of Additional Cancer DiagnosticsDr. Wang is the GI (Gastrointestinal) Division Chief at Columbia University Vagelos College of Physicians and Surgeons and serves as Co-leader of the Tumor Biology and Microenvironment Program of the Herbert Irving Comprehensive Cancer Center BERKELEY, Calif. and MAINZ, Germany, July 19, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the formation of a Medical Advisory Board (MAB), and the appointment of Dr. Timothy Wang as